Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib for Severe Alopecia Areata Long-Term Extension
CTR20220056Phase 3Completed
- Sponsor
- Suzhou Zelgen Biopharmaceuticals
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of jaktinib in alopecia areata, sponsored by Suzhou Zelgen Biopharmaceuticals. Primary endpoints: Incidence of treatment-emergent adverse events (TEAEs) at week 24, Incidence of serious adverse events (SAEs) at week 24 and 1 more. Started Feb 2022; status: completed.
02
Drugs
jaktinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on CTR20220056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220056.